News|Articles|August 1, 2024

Optimizing Oligonucleotide Analysis

Due to their ability to tackle targets that were considered undruggable, oligonucleotides represent a key cornerstone of the future of personalized medicine. This infographic presents the different types of therapeutic oligonucleotides and highlights some innovative solutions for their analysis.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 15th, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1

Nathan Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.

October 14th, 2026

The BioPharm Brief: Rare Disease, Trial Setbacks, and Oral Obesity

The FDA launches a new rare disease development initiative, BioNTech’s BNT113 misses a progression-free survival endpoint, and Viking Therapeutics begins Phase III trials of its oral obesity candidate.

3D illustration of a round red cell with a glowing orange nucleus at its center against a dark blue background. Evenly spaced around its surface are stylized receptors, each drawn as a chain of colored segments and dots ending in two parallel bars joined by a curved loop. | Image Credit: © Naeblys - stock.adobe.com

October 14th, 2026

After the Pivot: What In Vivo Cell Therapy Offers, and What It Still Has to Prove

As ArsenalBio, TScan, Bristol Myers Squibb, and others abandon ex vivo programs for in vivo engineering, early clinical data and platform differences point to both the promise and the unresolved safety, manufacturing, and regulatory questions of generating CAR-T cells inside the body.

A new FDA initiative targets consistency in rare disease drug review, including risk-based manufacturing oversight and earlier patient input. Credit: Stock.Adobe.com/Tada Images

October 14th, 2026

FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development

FDA’s rare disease framework effort will revisit evidence expectations and manufacturing review, with public input starting Oct. 28.

Doctor holding a digital tablet with x-ray of the 3D head of the patient with pain on the neck. Migraine headache concept | Image credit: © steph photographies - © steph photographies - stock.adobe.com

October 14th, 2026

BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial

BNT113 plus pembrolizumab failed to significantly extend progression-free survival in a 285-patient HPV16-positive head and neck cancer trial.

A scattered pile of round white tablets stamped “GLP-1” on a blue surface, with two light blue and white injection pens crossed on the right side of the frame. | Image Credit: © Andreas Prott - stock.adobe.com

October 14th, 2026

Viking Starts Phase 3 SUNRISE Program for Oral VK2735 in Obesity

Viking Therapeutics has started two Phase 3 trials of once-daily oral VK2735, a dual GLP-1/GIP receptor agonist, in adults with obesity, with and without type 2 diabetes.

T-cells attacking a cancer cell | Image credit: © frenta - © frenta - stock.adobe.com

October 14th, 2026

Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors

Gilead will develop up to three PRO-XTEN T-cell engagers discovered by Vir Biotechnology for solid tumors in a deal worth up to $1.74 billion.

A woman in light blue scrubs and a surgical mask holding the drip chamber below a clear IV bag hanging from a metal pole, with a stethoscope around her neck and a blurred office background. | Image Credit: © Elnur - stock.adobe.com

October 14th, 2026

FDA Accepts Resubmitted BLA for Tabelecleucel in EBV+ PTLD

The FDA has accepted Pierre Fabre Pharmaceuticals’ resubmitted BLA for tabelecleucel, an allogeneic T-cell immunotherapy for EBV+ post-transplant lymphoproliferative disease. The FDA’s target action date is March 31, 2027.

Optimizing Oligonucleotide Analysis

Related to this article

Trending on BioPharm International

FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review

FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development

Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors

BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial

Odyssey's OD-001-Vedolizumab Combo Advances to Phase 2a in UC